Virginia Commonwealth University and Institute of Molecular Medicine researchers developed a fusion molecule combining IL-24S and IL-15 cytokines to target glioblastoma’s immunosuppressive microenvironment. This “Fusion Superkine” simultaneously kills tumor cells and activates immune responses, potentially overcoming resistance to current therapies. Published in the Journal for ImmunoTherapy of Cancer, this approach aims to transform glioblastoma from an immune “cold” tumor to one responsive to immunotherapy.